#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can they win over skep­tics?

When As­traZeneca trum­pet­ed “mo­men­tous” and “trans­for­ma­tive” re­sults for Tagris­so ear­li­er this year at AS­CO, some prac­ti­tion­ers threw cold wa­ter on the ADAU­RA fer­vor. Sure, the dis­ease-free sur­vival da­ta look good, but over­all sur­vival is the end­point that mat­ters when it comes to choos­ing ad­ju­vant ther­a­py for non-small cell lung can­cer pa­tients, the ex­perts said.

The OS da­ta still aren’t here, but As­traZeneca is back at ES­MO to bol­ster their case with a look at brain metas­ta­sis da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.